MENU

Intellectual Property

Alnylam has an extensive portfolio of RNAi Intellectual Property (IP) with fundamental, chemistry, delivery, and target patents and patent applications covering the development and commercialization of RNAi therapeutics.

Alnylam’s IP estate includes a large number of issued patents and pending patent applications in the world’s major pharmaceutical markets- United States, European Union, and Japan, along with others throughout the world.   They cover synthetic RNA molecules, their synthesis and use, including use as therapeutics, diagnostics and research reagents.  We believe these patents and pending applications place Alnylam in the strongest possible position to not only build our company over the long-term and accelerate our efforts to bring life-saving drugs to patients in need,  but to enable other companies for advancement of RNAi therapeutics with licenses to our IP estate and associated know-how.  This belief has been validated by the progress of Alnylam to date with 11 programs in pre-clinical and clinical development and with over 30 distinct agreements entered into with leading pharmaceutical, biotechnology and research reagent companies.

Our IP can be categorized into three broad areas with exemplary granted patents in the major pharmaceutical markets:

show more

Fundamental IP

To view the issued claims select the PDF link below

United States

  • US 5,898,031: Crooke – PDF
  • US 6,107,094: Crooke – PDF
  • US 7,432,250: Crooke – PDF
  • US 7,695,902: Crooke – PDF
  • US 6,506,559: Fire and Mello – PDF
  • US 7,056,704: Tuschl II – PDF
  • US 7,078,196: Tuschl II – PDF
  • US 8,420,391: Tuschl I – PDF
  • US 8,445,237: Tuschl I – PDF
  • US 8,329,463: Tuschl II – PDF
  • US 8,362,231: Tuschl II – PDF
  • US 8,372,968: Tuschl II – PDF
  • US 8,394,628: Tuschl II – PDF
  • US 7,786,290: Woppmann – PDF

European Union

  • EP 928290: Crooke – PDF
  • EP 1550719: Kreutzer-Limmer – PDF
  • EP 1214945: Kreutzer-Limmer – PDF
  • EP 1309726 Tuschl I – PDF
  • EP 2361981 Tuschl I – PDF
  • EP 1407044 Tuschl II – PDF
  • EP 1873259 Tuschl II – PDF
  • EP 2348134 Tuschl II – PDF
  • EP 2351852 Tuschl II – PDF

Japan

  • JP 4 095 895: Tuschl II – PDF

Canada

  • CA 2 359 180: Kreutzer-Limmer – PDF
Less Content
show more

Chemistry and Delivery IP

To view the issued claims select the PDF link below

United States

  • US 5,859,221: Cook – PDF
  • US 6,153,737: Manoharan – PDF
  • US 7,078,196: Tuschl II – PDF
  • US 6,858,225: Semple – PDF
  • US 5,976,567: Wheeler – PDF
  • US 6,534,484: Wheeler – PDF
  • US 6,586,410: Wheeler – PDF
  • US 6,815,432: Wheeler – PDF
  • US 6,858,224: Wheeler – PDF
  • US 8,158,601: Chen – PDF
  • US 7,745,608: Manoharan – PDF
  • US 7,723,509: Manoharan – PDF
  • US 7,851,615: Manoharan – PDF
  • US 8,017,762: Manoharan – PDF
  • US 8,507,661: Manoharan – PDF
  • US 8,344,125: Manoharan – PDF
  • US 8,426,377: Manoharan – PDF
  • US 8,106,022: Manoharan – PDF
  • US 8,450,467: Manoharan – PDF
  • US 7,923,547: McSwiggen – PDF
  • US 7,956,176: McSwiggen – PDF
  • US 7,989,612: McSwiggen – PDF
  • US 8,232,383: McSwiggen – PDF
  • US 8,268,986: Beigelman – PDF
  • US 8,236,944: Beigelman – PDF
  • US 8,202,979: McSwiggen – PDF
  • US 8,273,866: McSwiggen – PDF
  • US 8,242,257: Beigelman – PDF
  • US 8,648,185: McSwiggen – PDF
  • US 13/693,478: Manoharan – PDF
  • 150 issued patents in-licensed from Isis – PDF

European Union

  • EP1423406: McSwiggen – PDF
  • EP2287306: McSwiggen – PDF
  • EP2278004: McSwiggen – PDF
  • EP1627061: McSwiggen – PDF
  • EP1458741: McSwiggen – PDF

United Kingdom

  • GB 2417727: Woppmann – PDF
Less Content
show more

Target IP

To view the granted or issued claim set select the PDF link below

United States

  • US 7,056,704: Tuschl II – PDF
  • US 8,618,277: McSwiggen – PDF

European Union

  • EP 1352061: Kreutzer-Limmer – PDF
  • EP 1349927: Kreutzer-Limmer – PDF
Less Content